Surveillance Versus Treatment for Favorable Intermediate‐Risk Prostate Cancer and Mortality‐Risk
The Prostate · 2026-05 · 86 (7) · 839-845
DOI: 10.1002/pros.70156 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Prostate, online erschienen am 09.03.2026. Verfasst von Mutlay Sayan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Active surveillance (AS) is the preferred management approach for patients with low‐risk prostate cancer (PC); yet whether younger patients with favorable‐intermediate‐risk (FIR) PC experience increased mortality‐risk when electing AS remains unknown. We evaluated all‐cause, PC‐specific, and non‐PC‐specific mortality (ACM, PCSM, and non‐PCSM) in younger patients with FIR PC managed with either AS/watchful‐waiting (WW) or immediate definitive treatment, stratified by race.
Methods
We conducted a retrospective cohort study using SEER data (2010–2020). Patients included were < 60 years‐old with FIR PC. The primary outcome was ACM, secondary outcomes PCSM and non‐PCSM. Multivariable Cox and Fine‐Gray competing‐risk regressions were used, adjusting for known prognostic factors. Interaction by race (White vs underrepresented minority [URM]) was explored. Statistical significance was set at p < 0.025 (Bonferroni‐adjusted).
Results
Among 3,832 patients, 127 died (3.31%), including 18 of the 127 deaths from PC (14.17%). Initial treatment with RP/RT did not significantly reduce ACM or non‐PCSM compared to AS/WW in White (ACM AHR, 0.92; 95% CI, 0.44–1.94; non‐PCSM AHR, 1.36; 95% CI, 0.53–3.46) or URM patients (ACM AHR, 0.68; 95% CI, 0.33–1.43; non‐PCSM AHR, 1.04; 95% CI, 0.44–2.44). However, after adjustment for multiplicity RP/RT significantly reduced PCSM‐risk compared to AS/WW in URM (AHR, 0.03; 95% CI, 0.00–0.48; p = 0.01), but not in White patients (AHR, 0.21; 95% CI, 0.05–0.88; p = 0.03) although the median follow‐up was 6.5‐months longer in URM patients undergoing AS/WW compared to RP/RT.
Conclusions
Early mortality‐risks were similar and low in patients age < 60 years with FIR PC managed with AS/WW compared to RP/RT, irrespective of race.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Statistics, Ankara University, Ankara, Türkiye.
- Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Jonathan E Leeman
Zitieren
APA
Sayan, M., Tuac, Y., Qian, Z., Dall, C. P., Cole, A. P., Leeman, J. E., King, M. T., Nguyen, P. L., & D'Amico, A. V. (2026). Surveillance Versus Treatment for Favorable Intermediate‐Risk Prostate Cancer and Mortality‐Risk. The Prostate, 86(7), 839-845. https://doi.org/10.1002/pros.70156
Vancouver
Sayan M, Tuac Y, Qian Z, Dall CP, Cole AP, Leeman JE, et al. Surveillance Versus Treatment for Favorable Intermediate‐Risk Prostate Cancer and Mortality‐Risk. The Prostate. 2026;86(7):839-845. doi:10.1002/pros.70156
BibTeX
@article{Sayan2026,
author = {Sayan, Mutlay and Tuac, Yetkin and Qian, Zhiyu and Dall, Christopher P and Cole, Alexander P and Leeman, Jonathan E and King, Martin T and Nguyen, Paul L and D'Amico, Anthony V},
title = {Surveillance Versus Treatment for Favorable Intermediate‐Risk Prostate Cancer and Mortality‐Risk},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {7},
pages = {839--845},
doi = {10.1002/pros.70156}
}
EUVIMED